Background: Long-chain nҀ3 polyunsaturated fatty acids have variable effects on LDL cholesterol, and the effects of docosahexaenoic acid (DHA) are uncertain. Objective: The objective of the study was to determine the effect on blood lipids of a daily intake of 0.7 g DHA as triacylglycerol in middle-aged men and women. Design: Men and women aged 40 -65 y (n ҃ 38) underwent a double-blind, randomized, placebo-controlled, crossover trial of treatment with 0.7 g DHA/d for 3 mo. Results: DHA supplementation increased the DHA concentration in plasma by 76% (P 0.0001) and the proportion in erythrocyte lipids by 58% (P 0.0001). Values for serum total cholesterol, LDL cholesterol, and plasma apolipoprotein B concentrations were 4.2% (0.22 mmol/L; P ҃ 0.04), 7.1% (0.23 mmol/L; P ҃ 0.004), and 3.4% (P ҃ 0.03) higher, respectively, with DHA treatment than with placebo. In addition, the LDL cholesterol:apolipoprotein B ratio was 3.1% higher with DHA treatment than with placebo (P ҃ 0.04), which suggested an increase in LDL size. Plasma lathosterol and plant sterol concentrations were unaffected by treatment. Conclusion: A daily intake of Ȃ0.7 g DHA increases LDL cholesterol by 7% in middle-aged men and women. It is suggested that DHA down-regulates the expression of the LDL receptor.
INTRODUCTION
The effect of mixtures of long-chain nҀ3 polyunsaturated fatty acids (nҀ3 LCPs) on plasma lipoproteins is well documented (1). Intakes 1.5 g/d lower plasma triacylglycerol concentrations, but the effects on LDL cholesterol are variable. An increase in LDL cholesterol has repeatedly been observed in subjects with the Type IV and Type V Fredrickson lipoprotein phenotypes. However, it was argued that the LDL-elevating effects of nҀ3 LCPs were similar to those observed for other triacylglycerol-lowering drugs in subjects with these phenotypes (2) . Minihane et al (3) in a post hoc analysis suggested that apolipoprotein E (Apo E) phenotype modulated the response to nҀ3 LCPs in subjects with the atherogenic lipoprotein phenotype. An increase in LDL cholesterol in subjects with the atherogenic lipoprotein phenotype of 15.9% in those carrying the 4 allele compared with 0.6% in those who were homozygous for the 3 allele was reported. It was suggested that subjects who were homozygous for the 3 allele did not show an increase in LDL after fish oil supplementation and that the increase in LDL cholesterol concentration was dependent on possession of the 4 allele.
Most studies of nҀ3 LCPs have generally used oils containing mixtures of eicosapentaenoic acid (20:5nҀ3; EPA) and docosahexaenoic acid (22:6nҀ3; DHA) in the range of 1-5 g/d. A few studies have examined the effects of DHA in hyperlipidemic subjects (4 -7) in the dose range of 3-4 g/d, usually provided as ethyl esters. Single-cell oil sources of DHA, which contain only trace amounts of EPA and other nҀ3 fatty acids, have become available for food use. Previous reports of the effects of such oils on lipoprotein concentrations have studied intakes in the range of 1.25-6 g/d and are limited by the small sample used and the short duration of the interventions (8 -10) .
Prospective cohort studies (11, 12) and a trial (13) of secondary prevention of ischemic heart disease suggested that intakes of 1 g nҀ3 LCPs/d offer protection from fatal ischemic heart disease. However, data from the study of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI study; 13) suggested than an ethyl ester preparation providing Ȃ0.85 g of a mixture of EPA and DHA in a ratio of 1.2:1 raised the LDL cholesterol slightly (3-3.5%). The primary aim of the present study was to evaluate the effect of a low intake of a triacylglycerol providing long-chain nҀ3 fatty acids almost exclusively as DHA in middle-aged subjects. As a consequence of the observed LDL-raising effect of DHA, a post hoc evaluation of the response according to Apo E genotype was conducted.
SUBJECTS, MATERIALS, AND METHODS
A randomized, double-blind, placebo-controlled, crossover design was chosen. Each treatment phase lasted 3 mo and was followed by a washout phase of ͧ 4 mo. Stratified randomization was used to allocate subjects to the 2 possible treatment sequences so that equal numbers of men and women were allocated to each sequence. The first phase was conducted between September 1999 and January 2000 and the second phase between April and August 2000. The study was conducted in a doubleblind fashion, but the analysis of plasma apolipoprotein B (apo B), lathosterol, and plant sterol concentrations and Apo E genotype were conducted post hoc. The study subjects were recruited by E-mail from within the staff population of King's College London, St Thomas's, Guy's, and King's College hospitals. Exclusion criteria were history of myocardial infarction or diabetes mellitus; current pregnancy; current use of lipid-or blood pressure-lowering medication, immunosuppressive drugs, or hormone replacement therapy; body mass index (BMI; in kg/m 2 ) 35; serum cholesterol 7.8 mmol/L; fasting serum triacylglycerol 3.0 mmol/L; blood pressure 160/105 mm Hg; abnormal results on hematologic or liver function test; and self-reported alcohol intake 21 units/wk for women and 28 units/wk for men (1 unit ҃ 10 mL ethanol). Subjects received a small financial incentive for their participation in the study. A small fasting venous blood sample (17 mL) was obtained for measurement of plasma total cholesterol, serum HDL cholesterol, plasma triacylglycerol, and a complete blood count and for performance of liver function tests. The serum concentration of follicle-stimulating hormone was measured in postmenopausal women, and a urinary pregnancy test was performed in menstruating women to confirm menopausal and nonpregnant status, respectively. Habitual dietary intake was assessed by using a 3-d weighed dietary record, the data from which were converted by computer to nutrient intake on the basis of the UK Nutrient Databank (Norwich, United Kingdom: Her Majesty's Stationery Office). Height without shoes and weight in minimum indoor clothing were measured with the use of a beam balance and stadiometer. The protocol was reviewed and approved by the Research Ethics Committee of King's College London, and participants gave written informed consent before commencing the study. After analysis of the results of the study, informed written consent was obtained from the subjects to determine their Apo E genotype.
The DHA treatment was provided as 3 capsules/d; each capsule contained 500 mg of a refined triacylglycerol derived from Crypthecodinium cohnii (DHASCO; Martek Biosciences, Columbia, MD). Matching placebo capsules contained 500 mg refined olive oil (British Pharmacopoiea specification). To ensure that the treatments had the same antioxidant content, the concentrations in the oils were standardized before encapsulation so that each capsule contained 4 tocopherol equivalents, 0.073 mg ␤-carotene, and 0.125 mg ascorbyl palmitate. Oils were flavored with peppermint to disguise the taste of the oil and were encapsulated in opaque gelatin capsules (RP Scherer, Swindon, United Kingdom). Capsules were stored at room temperature in a dry, dark place. Compliance with the treatment regimen was assessed by performing capsule counts and by measuring the incorporation of DHA into plasma and erythrocyte lipids.
At the start and at the end of each treatment period, subjects fasted overnight, and blood samples were obtained by venipuncture the following morning with the use of the evacuated-tube technique (Vacutainer; Vacutainer Systems, Becton Dickinson, Plymouth, United Kingdom). Blood for serum lipids and liver function tests was collected in an evacuated tube containing no anticoagulant (Vacutainer 17490; Becton Dickinson), serum was separated by centrifugation at 1500 ҂ g for 15 min at 4°C and kept at 4°C until it was analyzed, within 3 d. For full blood counts, blood was collected into Vacutainer tubes containing 2 mL potassium EDTA (Vacutainer 368047; Becton Dickinson) and kept at room temperature until the count on the same day. Blood for fatty acid, sterol, apo B, and fat-soluble vitamin analyses was collected into an EDTA-coated tube (Vacutainer 17644; Becton Dickinson) chilled to 4°C and centrifuged at 1500 ҂ g for 15 min at 4°C, and aliquots of plasma were frozen at Ҁ80°C until they were analyzed. Packed erythrocytes were washed 3 times with 5 volumes of ice-cold saline (8.9 NaCl/L) containing 40 mg EDTA/L, and lipid extracts were prepared within 2 d of blood collection by using isopropanol:chloroform (11:7 by volume) containing 50 mg butylated hydroxytoluene/L. The lipid extracts were stored at Ҁ20°C until they were analyzed. Blood (4.5 mL) for genetic analysis was collected into a Vacutainer tube containing 0.5 mL of 0.105 mol trisodium citrate/L (Vacutainer 367691; Becton Dickinson) and kept at room temperature until completion of centrifugation. Plasma was separated by centrifugation at 1500 ҂ g for 15 min a 4°C, and the remaining red and white blood cells were frozen at Ҁ40°C until they were analyzed.
Total and HDL cholesterol and triacylglycerol concentrations were measured with the use of fully enzymatic procedures using reagents from Wako (Neuss, Germany), and assays were conducted on a Technicon DAX48 automated chemistry analyzer (Bayer Diagnostics, Newbury, United Kingdom). Frozen plasma samples were analyzed for apo B concentration with the use of a commercially available immunoturbidimetric assay (Immuno AG, Vienna) on a Cobas Mira analyzer (Roche Diagnostics, Lewes, United Kingdom) as described previously (14) . Erythrocyte and plasma fatty acid concentrations were measured by using capillary gas chromatography (15) . Plasma sterols were extracted, trimethylsilyl derivatives were prepared (16) and analyzed by using capillary gas chromatography-mass spectrometry, and plasma fat-soluble vitamins were measured by using HPLC (17) . Genomic DNA was isolated from blood cells with the use of the "salting out" method, and the Apo E genotypes were determined (18) .
Statistical power calculations were based on the completion by 32 subjects of both treatments. These power estimates were based on within-subject SDs of 0.11 mmol/L and 0.29 mmol/L for HDL and LDL cholesterol, respectively. The sample size gave 80% power for ␣ ҃ 0.05 to detect a change of 0.08 mmol/L in HDL and a change of 0.2 mmol/L in LDL cholesterol. Forty subjects (20 men, 20 women) were recruited into each group to allow for dropouts. Data were analyzed by repeated-measures analysis of variance using SPSS/PC software (version 10; SPSS Inc, Chicago). Data for plasma triacylglycerol were log transformed before statistical analysis. Tests for treatment order effects were performed by using the technique described by Pocock (19) . If the overall repeated-measures analysis of variance was statistically significant (P 0.05), comparisons between active treatment and placebo were made by using a paired t test. Comparisons of the responses (active treatment Ҁ placebo) according to genotype were made by using analysis of covariance with adjustments for age, BMI, and sex. the women were premenopausal and 4 were postmenopausal. One subject (female) withdrew at the end of phase 1 for personal reasons. One subject (male) was excluded from the analysis because he was found to have a cardiac arrhythmia that was not treatment related and that thus violated the inclusion criteria for the study. Therefore, data on 38 subjects were available for analysis. The subjects' characteristics and their habitual dietary intakes are shown in Tables 1 However, over the yearlong study period, subjects showed a tendency to gain a small amount of weight (x : 1.0 kg; 95% CI: 0.54, 1.59 kg; P 0.0001).
Plasma concentrations of DHA increased by 76% during active treatment (from 59.9 Ȁ 4.5 mg/L during placebo treatment to 105.3 Ȁ 5.9 mg/L during DHA treatment; P 0.001). The proportion of DHA in erythrocyte phosphoglycerides increased by 58% (from 5.2 Ȁ 0.3% by wt during placebo treatment to 8.2 Ȁ 0.2% by wt during DHA treatment; P 0.001), and it is important that there was no evidence of any carryover effect between treatments (Figure 1) . The plasma concentrations of EPA were unaffected by the DHA treatment (1.4 Ȁ 0.1 mg/L during placebo treatment compared with 1.4 Ȁ 0.1 mg/L during DHA treatment), as were the proportion in erythrocyte lipids (1.1 Ȁ 0.1% by wt during placebo treatment compared with 1.2 Ȁ 0.1% by wt during DHA treatment).
The serum lipid and plasma apo B concentrations are shown in Table 3 . Repeated-measures analysis of variance found significant treatment effects for total cholesterol (P ҃ 0.001), LDL cholesterol (P ҃ 0.0001), and plasma apo B (P ҃ 0.002) concentrations. The increases during DHA treatment compared with those during placebo placebo were 0.22 mmol/L (95% CI: 0.01, 0.42 mmol/L; P ҃ 0.04) for total cholesterol, 0.23 mmol/L (95% CI: 0.08, 0.38 mmol/L; P ҃ 0.004) for LDL cholesterol, and 0.03 g/L (95% CI: 0.002, 0.055 g/L; P ҃ 0.03) for apo B. The LDL: apo B ratio also showed a significant treatment effect (P ҃ 0.004): the ratio was greater after DHA treatment than after placebo treatment (mean difference: 0.12 mol/mg; 95% CI: 0.004, 0.24 mol/mg; P ҃ 0.04). HDL cholesterol concentrations showed a significant treatment ҂ order effect (P ҃ 0.005) and a significant treatment effect (P ҃ 0.03). The 2 treatment sequences were thus analyzed separately. The values were significantly higher in the subjects who received DHA than in those who received placebo in the first treatment phase, which ran between fall (September and October) and midwinter (December and January; mean difference: 0.12 mmol/L; 95% CI: 0.02, 0.23 mmol/L; P ҃ 0.021) but not in the subjects who received DHA for the second phase, which ran between spring (March and April) and summer (July and August; mean difference: 0.02 mmol/L; 95% CI: Ҁ0.08, 0.12 mmol/L). Posttreatment values for serum triacylglycerol (Table 3) , plasma lathosterol, campesterol, and sitosterol concentrations did not differ significantly from pretreatment values ( Table 4 ). The cholesterol-adjusted concentration of plasma ␣-tocopherol increased slightly after supplementation with placebo treatment but remained unchanged after DHA treatment, but the posttreatment values with DHA treatment and with placebo treatment differed significantly. Plasma concentrations of retinol, ␤-carotene, lycopene, and lutein were unchanged (data not shown).
The changes in LDL cholesterol in subjects according to Apo E genotype with adjustment for age, BMI, and sex are shown in Figure 2 . The regression analysis did not show a significant genotype effect on the change in LDL cholesterol on treatment compared with placebo. The age-, BMI-, and sex-adjusted increase in LDL cholesterol for the subjects with the 3:3 genotype (n ҃ 23) was 8.1% (95% CI: 1.4%, 14.8%), that for those with the 3:4 genotype (n ҃ 10) was 6.7% (Ҁ4.2%, 17.6%), that for those with the 2:3 genotype (n ҃ 4) was Ҁ1.6% (95% CI: Ҁ17.6%, 14.5%), and that for the single subject with the 2:4 genotype was 29.6%.
DISCUSSION
The primary aim of the study was to ascertain the effects of Ȃ0.7 g DHA/d on serum lipids in healthy middle-aged subjects.
This relatively small amount of DHA had a remarkable effect on the plasma concentration of DHA and the proportion of DHA in erythrocytes. This finding is consistent with the recent study by Albert et al (20) that estimated both the intake of nҀ3 LCPs by using a food-frequency questionnaire and the proportions in total blood lipids in relation to the risk of sudden cardiac death.
Previous studies using DHA-rich oils have reported a significant reduction in triacylglycerol concentrations and an increase in HDL-cholesterol concentrations at DHA intakes of 1.62-6.0 g/d (4 -7). In the present study, no such triacylglycerol-lowering effect was observed with an intake of Ȃ0.7 g/d, which is consistent with the view that the minimum dose of nҀ3 LCPs that effectively lowers triacylglycerol concentrations is Ȃ1.5 g/d (1). Furthermore, the subjects of this study did not have elevated serum triacylglycerol concentrations. The within-subject SD for serum triacylglycerol was 0.32 mmol/L, which gave power to detect a change of 0.21 mmol/L in serum triacylglycerol, which was greater than the 0.18 mmol/L difference observed. Mori et al (5) reported an 8% increase in LDL cholesterol with 4 g ethyl esters of DHA/d. However, Nestel et al (6) were unable to show a statistically significant increase in LDL cholesterol with 3 g DHA-enriched ethyl ester concentrate ken taken daily for 7 wk by 12 subjects. Grimsgaard et al (7) compared 3.8 g EPA/d, 3.6 g DHA as ethyl esters/d, and 4.0 g corn oil/d taken for 7 wk, but they did not find any effect of DHA on LDL cholesterol. 5 HDL increased in subjects receiving DHA first. Significant treatment ҂ order effect, P ҃ 0.005. 6 n ҃ 37; data were log transformed before analysis by paired t test. 8 Weight increased over the entire study period. Significant order ҂ time effect, P ҃ 0.001.
TABLE 4
Serum lathosterol, ␤-sitosterol, and campesterol concentrations and ␣-tocopherol:cholesterol ratios adjusted for serum cholesterol concentrations before treatment and after 3 mo of docosahexaenoic acid (DHA) and placebo treatment in all subjects Hamazaki et al (21) also found no difference between the effect of DHA-rich fish oil capsules containing 1.5-1.8 g DHA and that of a control oil capsule containing 97% soybean oil and 3% fish oil for 13 wk on LDL cholesterol in young men. However, Davidson et al (4) reported a statistically significant (13.6%) increase in LDL-cholesterol concentrations in male subjects with combined hyperlipoproteinemia with the provision of 2.5 g DHA/d as an algal triacylglycerol similar to that used in the present study and a nonsignificant increase of 9.3% with the provision of 1.25 g DHA/d. These workers also reported a reduction in serum triacylglycerol concentrations and an increase in LDL particle size. Few controlled studies have examined the effects of nҀ3 LCP intakes 1 g/d on plasma lipids. Although results from the GISSI study (13) suggest a 3-0.3.5% LDL-elevating effect with 0.85 g ethyl esters of DHA and EPA/d, these results are confounded by changes in lipid-lowering therapy during the study. Higgins et al (22) compared the effect of fish oil providing a daily intake of 0.3, 0.6, and 0.9 g nҀ3 LCPs for 16 wk with that of placebo, with the use of a parallel design, and they failed to note any significant changes in plasma LDL cholesterol in healthy men and women. The striking finding in the present study was the LDL cholesterol-raising effect of a relatively modest intake of DHA. The increase was 7% greater than that seen with placebo. This observation is not likely to be due to chance, because the study had sufficient power to detect the observed change. Furthermore, we have confirmed this observation in a subsequent study (TAB Sanders, GJ Miller, unpublished observations, 2002) . Studies using purified EPA or EPA-rich oil have generally not reported increases in LDL cholesterol (1) . This observation may suggest that, when DHA is fed alone as a triacylglycerol, it has effects that differ from those when it is fed in combination with EPA as in fish oil. Although most of the subjects of the present study were moderately hypercholesterolemic (serum cholesterol 5 mmol/L), they were healthy men and women who were generally representative of this age group in the United Kingdom. Indeed, their BMI, blood pressure, and serum cholesterol concentrations were lower than the average (23) . The results from this study, therefore, can be generalized to most of the British men and women in this age group. In support of this, the frequency of the 4 and 2 alleles did not differ significantly from that found by other UK studies (24) . The increase in LDL was confirmed by the post hoc analysis of plasma apo B concentration. However, the LDL cholesterol:apo B ratio was greater after the DHA treatment, which may suggest that the LDL particle size was increased. This finding is in agreement with findings of a study using ethyl esters of DHA that made direct measurements of LDL size (5), a study using fish oil (3), and a study using an algal triacylglycerol preparation similar to that in the present study (6) . Because small, dense LDL particles are associated with an increased risk of heart disease (25), it has been argued (3) that they are more susceptible to oxidation and more atherogenic than are those of a lower density (5) . Consequently, the potentially greater risk associated with the increase in LDL-cholesterol concentration may be ameliorated by an increase in LDL particle size.
The reasons for variability in response to DHA are uncertain. Minihane et al (3) suggested that the increase in LDL cholesterol was greatest in men carrying the ⑀4 allele but not significant in men who were homozygous for the ⑀3 allele. However, their results did not differ significantly by genotype. In the present study, we were able to show that the LDL-cholesterol concentration increased with DHA supplementation in men and women who were homozygous for the ⑀3 allele. However, the study was not powered to detect differences in response between genotypes, and further research using a much larger sample size is required to establish whether there is difference in response according to genotypes.
Plasma lathosterol and phytosterol concentrations were measured post hoc as indexes of cholesterol synthesis and absorption (26) , but these concentrations were not found to be altered by DHA treatment. Consequently, it would appear that mechanisms other than cholesterol synthesis and absorption are likely to be responsible for the increase in LDL cholesterol. Feeding fish oil containing DHA to hamsters (27) and primates (28) results in decreased receptor-mediated clearance of LDL, which could be a result of either decreased binding of LDL to the LDL receptor or decreased expression of LDL receptor. The latter now seems a likely mechanism because, in vitro, DHA down-regulates LDL receptor expression in HepG2 cells (29) . DHA is a physiologic ligand for several nuclear hormone receptors-in particular, the peroxysome proliferator-activated receptor and the liver X receptor-which play an important role as lipid sensors in regulating lipid metabolism (30 -32) . DHA may decrease the expression of LDL receptors by down-regulating the transcription or degradation of sterol regulatory element-binding protein. Alternatively, it may lead to the generation of oxysterols within the liver that stimulate the liver X receptor. Further research is needed to clarify the reasons for the increase in LDL cholesterol with low intakes of DHA.
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